CNN (8/1, McPhillips) reports that “amid an ongoing shortage of prescription stimulants in the US, federal agencies are calling on drugmakers to boost manufacturing and on health care [practitioners] to closely monitor prescribing practices.” FDA Commissioner Robert Califf and Drug Enforcement Administration leader Anne Milgram wrote in a joint letter on Tuesday, “The FDA and DEA do not manufacture drugs and cannot require a pharmaceutical company to make a drug, make more of a drug, or change the distribution of a drug. … That said, we are working closely with numerous manufacturers, agencies, and others in the supply chain to understand, prevent, and reduce the impact of these shortages.”
The Hill (8/1, Shapero) reports the DEA and the FDA “laid out steps they are taking to mitigate the ongoing shortage of prescription stimulants.” Milgram and Califf “said their agencies are calling on drug manufacturers to increase production of prescription stimulants to meet their allotted quotas for the year and urging those who do not want to boost production to relinquish the rest of their allotment so it can be redistributed.”
Related Links:
— “FDA, DEA call on drugmakers to boost manufacturing amid ongoing shortage of prescription stimulants,”Deidre McPhillips, CNN, August 1, 2023